http://www.phrma.org/press/newsreleases//2001-12-17.318.phtml
December 17, 2001
A new survey found 176 new medicines
in development for neurologic diseases - up from 138 when the previous
survey was conducted in 1999. More than 100 pharmaceutical and biotechnology
companies are conducting this research, according to the Pharmaceutical
Research and Manufacturers of America (PhRMA).
"Pharmaceutical company researchers
are using significant new knowledge about how the brain works to help patients
with Alzheimer's, stroke, Parkinson's and other diseases," said PhRMA President
Alan F. Holmer.
The potential new medicines include:
"These new medicines, and the pharmaceutical
industry's continuing investment in research on diseases of the central
nervous system, are grounds for hope that some of the cruelest of human
afflictions may have better treatments and, one day, cures," said Holmer.
The Pharmaceutical Research and Manufacturers
of America (PhRMA) represents the country's leading research-based pharmaceutical
and biotechnology companies, which are devoted to inventing medicines that
allow patients to live longer, healthier, and more productive lives. Investing
more than $30 billion in 2001 in discovering and developing new medicines,
PhRMA companies are leading the way in the search for new cures.
Other medicines being developed target
amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease), head injuries,
Huntington's disease, neuropathies, sleep disorders, spinal cord injuries,
lupus and other diseases. All of these medicines are either in human clinical
trials or awaiting approval by the U.S. Food and Drug Administration.